

Enrolling Kidney Cancer Studies at Urology of Virginia

Argos Therapeutics, Inc. “A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib”

This study is designed for patients who are diagnosed with advanced renal cell carcinoma and will undergo a partial or complete nephrectomy. The purpose of the study is to investigate an anticancer immunotherapeutic, AGS-003 when used in combination with sunitinib (the “standard of care” treatment regimen).

ECOG 2805 ASSURE “A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma”

For patients with locally advanced renal cell carcinoma, this study will compare three treatment arms of oral medication or placebo. Qualified patients who will undergo a nephrectomy are eligible. Study participants will receive extensive follow up with scans and visits during the course of the study. The study will measure disease-free survival.